Antimicrobial Peptides as Potential Treatments for Leishmaniasis and Other Parasitic Diseases | Research

The takeaway

Multiple families of antimicrobial peptides — including melittin, cathelicidin, defensins, and magainin — show anti-parasitic activity against Leishmania, offering alternatives to drug-resistant conventional treatments.

9 AMP families active
Nine different antimicrobial peptide families have demonstrated anti-leishmanial activity, from bee venom melittin to human cathelicidins and defensins

What the researchers found

Nine AMP families (melittin, cecropin, cathelicidin, defensin, magainin, temporin, dermaseptin, eumenitin, histatin) demonstrate anti-leishmanial activity through direct lysis and immune modulation, offering alternatives to drug-resistant conventional treatments.

Why it matters

Leishmaniasis affects millions in tropical regions and current drugs are increasingly failing due to resistance. AMPs with dual-action mechanisms (direct killing + immune boosting) could provide much-needed new treatment options.

The numbers in context

9 AMP families; mechanisms: membrane lysis and immune modulation; leishmaniasis is #2 parasitic disease after malaria

How the study worked

Narrative review of published literature on antimicrobial peptide activity against Leishmania and other parasites, covering mechanisms of action, major peptide families, and therapeutic potential.

Who was studied

Review of studies on AMPs active against Leishmania and other parasites

What this study cannot tell us

Review of mostly preclinical data. AMP stability, toxicity, production costs, and delivery challenges remain significant barriers to clinical use. Most anti-leishmanial testing has been in vitro.

How to read the evidence

Not applicable (narrative review). Based primarily on in vitro and preclinical anti-parasitic testing data.

When this study was published

Published in 2021. AMP research for parasitic diseases continues to advance with synthetic peptide optimization.

The bigger picture

AMPs are emerging as broad-spectrum anti-infective agents. Their activity against parasites like Leishmania, in addition to bacteria, viruses, and fungi, highlights their versatility and potential as a new class of therapeutics for neglected tropical diseases.

Questions still open

Which AMP family offers the best balance of anti-leishmanial potency and low toxicity for clinical development?
Can AMPs be combined with existing anti-leishmanial drugs to overcome resistance?
Would topical AMP formulations be effective for cutaneous leishmaniasis?

Common questions

What is leishmaniasis and why are new treatments needed?

Leishmaniasis is a parasitic disease transmitted by sandflies that affects millions of people in tropical regions. Current treatments based on antimonial compounds are increasingly failing due to drug resistance and can cause serious side effects.

How could antimicrobial peptides treat parasitic infections?

AMPs fight parasites in two ways: they can directly destroy parasite cell membranes (direct lysis) and they can stimulate the immune system to better fight the infection (immune modulation). This dual mechanism makes resistance harder for parasites to develop.

Read the original research

Activity of Anti-Microbial Peptides (AMPs) against Leishmania and Other Parasites: An Overview.

Biomolecules, 11(7)

View on PubMed ↗Publisher’s paper ↗

Citation

El-Dirany, Rima; Shahrour, Hawraa; Dirany, Zeinab; Abdel-Sater, Fadi; Gonzalez-Gaitano, Gustavo; Brandenburg, Klaus; Martinez de Tejada, Guillermo; Nguewa, Paul A. (2021). Activity of Anti-Microbial Peptides (AMPs) against Leishmania and Other Parasites: An Overview.. Biomolecules, 11(7). https://doi.org/10.3390/biom11070984